A transformation needs to take place in the way we manufacture and deliver adult stem cell therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An Integrated Miniature Bioprocessing for Personalized Human Induced Pluripotent Stem Cell Expansion and Differentiation into Neural Stem Cells
Scientific Reports Open Access 06 January 2017
-
Osseous differentiation of human fat tissue grafts: From tissue engineering to tissue differentiation
Scientific Reports Open Access 05 January 2017
-
Mesenchymal stem cell-based therapy in kidney transplantation
Stem Cell Research & Therapy Open Access 07 February 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Abdallah, B.M. & Kassem, M. Gene Ther. 15, 109–116 (2008).
Glotzbach, J.P. Curr. Probl. Surg. 48, 148–212 (2011).
Thomas, R. & Williams, D.J. Pharmatech 33, 74–79 (2009).
Halme, D.G. & Kessler, D. N. Engl. J. Med. 355, 1730–1735 (2006).
Huang, X.-P. et al. Circulation 122, 2419–2429 (2010).
Atoui, R. & Chiu, R. Stem Cells Trans. Med. 1, 200–205 (2012).
Porter, D.L. Hematology (Am. Soc. Hematol. Educ. Program) 2011, 292–298 (2011).
Hakimian, R. & Korn, D. J. Am. Med. Assoc. 292, 2500–2505 (2004).
Freeman, M. & Fuerst, M. J. Transl. Med. 10, 60 (2012).
Cosh, E., Girling, A., Lilford, R., McAteer, H. & Young, T. J. Commerc. Biotechnol. 13, 263–271 (2007).
O'Brien, J. Fortune http://fortune.com/2012/09/28/the-great-stem-cell-dilemma/ (8 October 2012).
Anonymous. Inbound Logistics 30, 75–76 (2010) http://www.inboundlogistics.com/cms/article/just-chill-moving-live-tissue/.
Denault, J., Coquet, A. & Dodelet, V. BioProcess Int. 6, 14–23 (2008).
Martin, I., Smith, T. & Wendt, D. Trends Biotechnol. 27, 495–502 (2009).
Santoro, R. et al. Biomaterials 31, 8946–8952 (2010).
US Food and Drug Administration. Guidance for Industry: Cell selection devices for point of care production of minimally manipulated autologous peripheral blood stem cells (PBSCs) http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0290-gdl0001.pdf (US Department of Health and Human Services, 2007).
Acknowledgements
We would like to acknowledge the support of Health Technology Exchange (HTX), National Science and Engineering Research Council (NSERC) and Ontario Centres of Excellence (OCE).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors work for Octane Biotech Inc., a company that develops and manufactures bioreactor automation systems for clinical applications.
Rights and permissions
About this article
Cite this article
Trainor, N., Pietak, A. & Smith, T. Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol 32, 729–735 (2014). https://doi.org/10.1038/nbt.2970
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2970
This article is cited by
-
Biomanufacturing for clinically advanced cell therapies
Nature Biomedical Engineering (2018)
-
An Integrated Miniature Bioprocessing for Personalized Human Induced Pluripotent Stem Cell Expansion and Differentiation into Neural Stem Cells
Scientific Reports (2017)
-
Osseous differentiation of human fat tissue grafts: From tissue engineering to tissue differentiation
Scientific Reports (2017)
-
Mesenchymal stem cell-based therapy in kidney transplantation
Stem Cell Research & Therapy (2016)
-
Characterization of a Self-renewing and Multi-potent Cell Population Isolated from Human Minor Salivary Glands
Scientific Reports (2015)